Express News | AEON Biopharma Q3 2024 GAAP EPS $(0.16), Inline
AEON Biopharma | 8-K: AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
AEON Biopharma | 10-Q: Q3 2024 Earnings Report
AEON Biopharma 3Q Loss/Shr 16c >AEON
Press Release: AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
AEON Biopharma Releases New Investor Presentation
12 Health Care Stocks Moving In Friday's Intraday Session
H.C. Wainwright Maintains AEON Biopharma(AEON.US) With Buy Rating, Maintains Target Price $5
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $5 Price Target
Buy Rating on AEON Biopharma: Strategic FDA Alignment and Positive Long-Term Revenue Projections
Express News | AEON Biopharma Says Is Aligned With FDA On Next Steps For 351(k) Regulatory Pathway To Approval For ABP-450 As A Biosimilar Utilizing BOTOX As The Reference Product
Express News | AEON Biopharma Inc - Comparative Analytical Studies Anticipated to Commence in Q4 2024
AEON Biopharma Announces Positive Outcome From FDA Biosimilar Advisory Meeting
Express News | Aeon Biopharma Files For Class A Common Stock Offering Of Up To $50M
Express News | AEON Biopharma Inc Files for Class a Common Stock Offering of up to $50.0 Mln - SEC Filing
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Express News | AEON Biopharma Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing
H.C. Wainwright Maintains AEON Biopharma(AEON.US) With Buy Rating, Cuts Target Price to $5
HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $5
No Data
No Data